Niki BioSolutions presents H.C. Wainwright slides, details merger, product pipeline and near-term revenue sources

Niki BioSolutions disclosed its corporate presentation highlighting the Aptorum—DiamiR all-stock merger completion, validated assays, and near-term pharma services revenue.Key Highlights:Original SEC Filing: Niki BioSolutions, Inc. [ NIKI ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may…